Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Meniere Disease - Overview
Meniere Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Meniere Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Meniere Disease - Companies Involved in Therapeutics Development
Adare Pharma Solutions
Apsen Farmaceutica SA
IntraBio Ltd
Quark Pharmaceuticals Inc
Sound Pharmaceuticals Inc
Steel Therapeutics Inc
Synphora AB
Meniere Disease - Drug Profiles
APSLXR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
betamethasone valerate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Meniere’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ebselen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-2000s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPHL-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Meniere Disease - Dormant Projects
Meniere Disease - Product Development Milestones
Featured News & Press Releases
Jun 08, 2020: Sound Pharma advances pivotal Phase 3 clinical trials in Meniere’s Disease
Sep 18, 2019: FDA grants Fast Track Desigtion for SPI-1005 in the treatment of Meniere’s Disease
Jun 25, 2019: Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere’s Disease clinical trial
Mar 20, 2019: Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere’s Disease clinical trial
Mar 06, 2019: Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere’s Disease clinical trial
Oct 03, 2017: Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Menieres Disease
Jun 27, 2017: Sound Pharmaceuticals completes enrollment on Meniere’s Disease clinical trial
Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use
Jan 05, 2016: FDA allows Sound Pharmaceuticals to begin Meniere Disease clinical trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Meniere Disease, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Meniere Disease, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Meniere Disease - Pipeline by Adare Pharma Solutions, 2021
Meniere Disease - Pipeline by Apsen Farmaceutica SA, 2021
Meniere Disease - Pipeline by IntraBio Ltd, 2021
Meniere Disease - Pipeline by Quark Pharmaceuticals Inc, 2021
Meniere Disease - Pipeline by Sound Pharmaceuticals Inc, 2021
Meniere Disease - Pipeline by Steel Therapeutics Inc, 2021
Meniere Disease - Pipeline by Synphora AB, 2021
Meniere Disease - Dormant Projects, 2021